INCRHealthcare · Drug Manufacturers - Specialty & GenericTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 9 of 100 as at 12 Sept 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores InterCure Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (81): The share price has been relatively steady.
Growth (1): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on INCR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 11 most recent actions, 5 moved their price target up and 5 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 12 Apr 2023 | TD Cowen | Maintains | Outperform | $10 → $5.00 |
| 11 Dec 2017 | Barclays | Initiates | Equal-Weight | $40 |
| 14 Nov 2017 | Credit Suisse | Maintains | Outperform | $68 → $54 |
| 13 Nov 2017 | Keybanc | Maintains | Overweight | $68 → $46 |
| 10 Nov 2017 | Baird | Maintains | Outperform | $67 → $46 |
| 17 Aug 2016 | Jefferies | Maintains | Buy | $56 → $55 |
| 12 Aug 2016 | Goldman Sachs | Maintains | Buy | $60 → $62 |
| 18 Apr 2016 | Avondale Partners | Maintains | Market Perform | $39 → $47 |
| 1 Sept 2015 | Jefferies | Upgrade | Buy | $50 → $51 |
| 27 May 2015 | Jefferies | Maintains | Hold | $35 → $37 |
| 12 Feb 2015 | Baird | Upgrade | Outperform | $26 → $29 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. INCR appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 11 Sept 2026, InterCure Ltd. returned +232.9% against +17.5% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 34% of US stocks
Cheaper than 89% of US stocks
Cheaper than 81% of US stocks
Cheaper than 38% of US stocks
Higher than 73% of US stocks
Higher than 45% of US stocks
Higher than 37% of US stocks
Higher than 25% of US stocks
Higher than 18% of US stocks
Higher than 36% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
InterCure Ltd. has a market value of $77.4M and an enterprise value of $214.0M.
Revenue in the twelve months to 30 June 2023: $414.8M. The latest quarter grew 23.9% year on year.
Net income over the same four quarters: $17.4M, a 4.2% net margin.
Trailing P/E: 22.2×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.
InterCure Ltd. employs 285 people — $1.5M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own InterCure Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
InterCure Ltd. announced that it has regained compliance with the Nasdaq minimum bid price requirement. The company made this announcement from its offices in New York and Herzliya, Israel on September 8, 2026.
Why it matters — Regaining compliance removes the risk of delisting related to the bid price rule, helping maintain InterCure's continued listing on Nasdaq.
InterCure Ltd. finalized a NIS 230 million (~US$77 million) settlement related to indirect damages from the war. The company plans to use these funds to accelerate rehabilitation of Canndoc's flagship Nir Oz facility, aiming to return to full production and support expansion in the German medical cannabis market.
Why it matters — The settlement provides InterCure with a substantial cash influx that could help restore its key production facility and strengthen its position in the growing German medical cannabis market.
Of the 12 analysts covering InterCure Ltd., 8 rate it a Buy, 4 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks InterCure Ltd. 9 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 12 Sept 2026, InterCure Ltd. ranks 9 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (81 of 100).
No analyst covering InterCure Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for INCR are extrapolating price history, which says nothing about the business.
InterCure Ltd. returned +232.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
InterCure Ltd. is an Israel-based pharmaceutical cannabis company focused on the production, manufacturing, and distribution of medical cannabis products.
The most recent item we track (GlobeNewsWire, 8 Sept 2026): "InterCure Regains Compliance with Nasdaq Minimum Bid Price Requirement". InterCure Ltd. announced that it has regained compliance with the Nasdaq minimum bid price requirement. The company made this announcement from its offices in New York and Herzliya, Israel on September 8, 2026.
InterCure Ltd. is an Israel-based pharmaceutical cannabis company focused on the production, manufacturing, and distribution of medical cannabis products. Through its subsidiaries, it develops and supplies pharmaceutical-grade dried cannabis inflorescences and cannabis extracts for medical use in Israel and international markets. The company also operates in the broader biomed sector, reflecting a business mix that combines cannabis operations with investments in healthcare-related portfolio companies. InterCure serves patients, healthcare providers, and distribution partners through a vertically integrated model that spans research, cultivation, production, and delivery of cannabis-based therapies. Headquartered in Herzliya, Israel, InterCure plays a significant role in the regulated medical cannabis market by emphasizing clinical-grade standards and licensed production capabilities.
CEO Mr. Alexander Rabinovich · 285 employees · Israel · https://www.intercure.co
